Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zogenix and Battelle have announced an agreement to advance the development and commercialization of Zogenix's DosePro drug delivery technology outside Zogenix's core therapeutic focus areas.
Subscribe to our email newsletter
The companies have signed a letter of intent to enter into co-marketing and technology development option agreement to utilize Zogenix’s DosePro needle-free drug delivery technology for new commercial out-licensing opportunities.
The Letter of Intent contemplates that upon successful out-licensing of DosePro, Battelle will have the option to participate directly in further development of the DosePro technology.
DosePro technology enables needle-free medication delivery under the skin.
DosePro technology uses a small amount of compressed gas to deliver a liquid formulation through the skin as a thin jet of medication.
Zogenix DosePro Technology vice president and general manager John Turanin said that DosePro can provide sustainable competitive advantages for many injectable drugs, especially biologics.